原发性血小板增多症
医学
骨髓纤维化
髓样
骨髓增生性肿瘤
真性红细胞增多症
协商一致会议
疾病
内科学
髓系白血病
肿瘤科
骨髓
作者
Jürgen Thiele,Hans Michael Kvasnicka,Attilio Orazi,Umberto Gianelli,Naseema Gangat,Alessandro M. Vannucchi,Tiziano Barbui,Daniel A. Arber,Ayalew Tefferi
摘要
Abstract A group of international experts, including hematopathologists, oncologists, and geneticists were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World Health Organization classification system for hematopoietic tumors. After careful deliberation, the group introduced the new International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias. This current in‐depth review focuses on the ICC‐2022 category of JAK2 mutation‐prevalent myeloproliferative neoplasms (MPNs): essential thrombocythemia, polycythemia vera, primary myelofibrosis, and MPN, unclassifiable. The ICC MPN subcommittee chose to preserve the primary role of bone marrow morphology in disease classification and diagnostics, while also acknowledging the complementary role of genetic markers for establishing clonality, facilitating MPN subtype designation, and disease prognostication.
科研通智能强力驱动
Strongly Powered by AbleSci AI